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disributions. RESULTS: In the base case, NA-E was found to be
the most cost-effective alternative. NA-E cost 321UAH (1
USD = 5.05 UAH) compared to 930UAH for D-E, 1319UAH for
transdermal N-E to prevent a single pregnancy per patient per
year. Monte –Carlo sensivity analysis conﬁrmed these ﬁndings.
CONCLUSION: The cost-effectiveness ratio NA-E dominated
all contraceptive strategies.These direct medical costs, in turn,
were driven by differential compliance that favored NA-E.
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OBJECTIVE: To conduct a cost-effectiveness analysis of contra-
ceptives available in the United States from a payer’s perspective.
METHODS: A Markov model was constructed to simulate
method failure (deﬁned as ectopic pregnancy, abortion, or full-
term birth) and costs among 17 contraceptive methods over a
5-year period: vasectomy, tubal ligation, injectable, implant,
copper-T IUD, LNG-20 IUS, oral contraceptives, diaphragm,
male condom, female condom, spermicides, sponge, patch,
NuvaRing, withdrawal, periodic abstinence and no method. In
each yearly cycle, subjects transition to “continue contracep-
tion”, “method failure” or “plan disenrollment”. Subjects
remain on the method for the model duration after method
failure or adverse effect. We assumed that 60% of unintended
births are mistimed and would occur two years later. Failure rate,
adverse event rates, and resource utilization were derived from
comprehensive literature review and supplemented with expert
opinion. Unit costs were obtained from published fee schedules
and drug prices. Future costs and effectiveness were discounted at
3%/year. Sensitivity analyses were performed on cost and failure
rates. RESULTS: Any contraceptive method is superior to “no
method” in terms of costs and success rate. The three least
expensive methods were copper-T IUD ($645), vasectomy ($713)
and LNG-20 IUS ($930). The most effective methods (99.6%
success rate) were vasectomy, implant, tubal ligation, LNG-20
IUS and copper-T IUD. Results were sensitive to variations in
cost of contraception method, cost of unintended pregnancy and
plan disenrollment rates. Moreover, with a longer time horizon,
methods with high initial costs (ie, copper-T IUD, vasectomy
and LNG-20 IUS) and high effectiveness rates become more
cost-effective. CONCLUSION: Copper-T IUD, vasectomy and
LNG-20 IUS are among the most effective methods currently
available in the US market. This analysis demonstrates that dif-
ferences in efﬁcacy, method costs, cost of unintended pregnancies
and time horizon are inﬂuential factors that determine the overall
value of a contraception method.
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OBJECTIVE: To estimate the cost-effectiveness of screening
for vasa previa at 18–20 weeks gestation. Several screening
strategies were considered for singleton and twin pregnancies.
METHODS: We constructed a decision-analytic model to esti-
mate the incremental costs and beneﬁts associated with screening
for vasa previa at 18–20 weeks gestation. We compared the
status quo of not screening to scenarios in which all singleton and
twin pregnancies were screened using transvaginal color Doppler
ultrasound. We also considered strategies in which only high-risk
pregnancies were screened. Costs were collected primarily from
the London Health Sciences Centre case costing initiative and
from the OHIP Schedule of Beneﬁts for Physicians. Other data
estimates were obtained from published sources and expert
opinion. Health beneﬁts were measured in life-years (LY) gained.
Costs and health beneﬁts were estimated for a cohort of preg-
nancies in Ontario in 1 year. RESULTS: Compared to not screen-
ing, screening all twin pregnancies for vasa previa has an
incremental cost effectiveness ratio (ICER) of less than $10,000
per LY gained. Among all risk factors in singleton pregnancies,
velementous cord insertion is the strongest predictor of vasa
previa. Identifying and screening pregnancies affected by vela-
mentous cord insertion has an ICER of less than $10,000 per LY
gained compared to not screening. Compared to screening only
pregnancies identiﬁed as having a velamentous cord insertion,
screening all pregnancies has an ICER of approximately $75,000
per LY-gained. Compared to screening for vasa previa in
pregnancies identiﬁed as having any high risk indicator, routine
screening of all pregnancies has an ICER of over $100,000 per
LY gained. CONCLUSION: A strategy of screening all twin and
all high-risk singleton pregnancies for vasa previa has a very low
incremental cost effectiveness ratio and should be considered for
adoption. However, routine screening of all pregnancies is not
likely to be cost effective.
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OBJECTIVE: Prophylactic therapy with palivizumab, a human-
ized monoclonal antibody, reduces the number of respiratory
syncytial virus (RSV)-related hospitalizations in preterm infants,
including those in the 32 to 35 weeks gestational age (GA)
subgroup. The cost-effectiveness of this therapy in Canada is
unknown. To evaluate the cost-effectiveness of palivizumab as
respiratory syncytial virus prophylaxis in premature infants born
at 32 to 35 weeks GA, from both the payer (base-case) and
societal perspectives. METHODS: A decision analytic model was
designed to compare costs and beneﬁts of prophylaxis in this
subgroup of premature infants. Sensitivity analyses were per-
formed to ascertain the robustness of the model by varying
mortality, health utilities, discount rates and administration
costs. SETTING: Canadian publicly funded health care system
(base-case analysis). PARTICIPANTS: Canadian infants born at
32 to 35 weeks gestation without chronic lung disease. INTER-
VENTIONS: Palivizumab prophylaxis versus no prophylaxis.
MAIN OUTCOME MEASURES: Expected costs and incremen-
tal cost-effectiveness ratio expressed as cost per quality-adjusted
life-year (QALY) gained using $CAN 2006. RESULTS: The
expected costs were higher for palivizumab prophylaxis as com-
pared with no prophylaxis. The incremental cost-effectiveness
ratio for the base-case scenario was $16,605 per QALY after
discounting, which is considered cost-effective. Sensitivity analy-
ses showed the model was robust through reasonable estimates
of key variables. Sub-analyses that varied risk of RSV based on
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the validated, Canadian risk scoring model were sensitive to
the resulting variation in RSV-related hospitalization rates. In
instances where risk was low, palivizumab was not cost-effective.
However, for infants with at least moderate risk (2 or more risk
factors), palivizumab had incremental costs per QALY that indi-
cated moderate to strong evidence for adoption (range: $1,598 to
$30,819 per QALY). CONCLUSION: Palivizumab was cost-
effective and our model supports prophylaxis for infants born at
32 to 35 weeks GA, particularly those with moderate risk of
RSV.
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To make appropriate use of the growing economic evidence
base in health care, developing countries need applications rel-
evant to their own national health objectives. One objective is
protection for individuals and governments against the ﬁnancial
risks of ill health, more critical in low-resource settings. Yet,
advancements in cost-effectiveness analysis (CEA) have not
focused on the importance of efﬁciency in contributing to this
goal. The lowest income nations also rely heavily on external
funds from donor countries and organizations. While the recent
emergence of non-traditional donors has greatly increased
funding levels for global health, the large scale, narrow focus
and time limitations of some of the funding have also raised
questions of their effects on national health priorities as well as
on the opportunity costs of the interventions supported by this
funding. In attaining efﬁciency with a view towards minimizing
ﬁnancial risk, CEA must address two issues in this case: that the
additional resources are efﬁciently allocated and that the
resources themselves are not a source of ﬁnancial risk. This
doctoral project proposes a conceptual framework for a CEA
“reference case” in the broader context of health ﬁnancing in
developing countries. Suggested modiﬁcations of the prevailing
reference cases are literature-based, iteratively guided by key
informants. Costing and sensitivity analysis with respect to
external funding are highlighted. An application to the intro-
duction of rotavirus immunization illustrates the framework.
The conceptual framework anticipates the imminent introduc-
tion of expensive new vaccines targeted at resource-poor, donor-
dependant health systems. It allows analysts and policy-makers
to harmonize efﬁciency and ﬁnancial risk objectives. It also
helps donors in assessing aid effectiveness of assisted programs.
Ultimately, this framework improves the transferability and gen-
eralizability of existing CEA results by suggesting adjustments
relevant to developing countries.
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OBJECTIVE: Treatment of preterm labour constitutes consider-
able inpatient cost, and use of tocolytics is central in delaying
birth to allow neonatal lungs to mature. The study aimed to
compare cost implications of adverse events following tocolysis
with atosiban and beta-mimetics. METHODS: Major literature
databases were systematically searched to identify randomised
clinical trials comparing atosiban with beta-mimetics during the
initial 48 h of hospitalisation. Adverse events data from three
double blind trials were included in a meta-analysis. Clinical
resource use was determined based on routine practice in a
regional German hospital. Cost of drug treatment was calculated
based on trial protocols and German hospital drug purchase
costs; analysis was performed for fenoterol, the only beta-
mimetic licensed in Germany for tocolysis. Costs per case were
calculated with G-DRG Grouper. Costs were expressed in €2007.
RESULTS: Use of atosiban was associated with signiﬁcantly
lower frequency of adverse events compared to beta-mimetics.
From the payer’s perspective, cost-saving from using atosiban
versus fenoterol was €423 per patient starting treatment. From
the hospital’s perspective, savings from using atosiban versus
continuous fenoterol ranged from €259 for 18 hours of tocolysis
to €105 for 48 hours; the respective values for bolus fenoterol
were €244 and €55. From the combined perspective, using
atosiban versus continuous fenoterol saved from €226 for 18
hours of tocolysis to €71 for 48 hours; versus bolus fenoterol the
results were €211 and €21, respectively. In the probabilistic sen-
sitivity analysis atosiban was cost-saving versus both continuous
and bolus fenoterol in 100% of iterations at 18 hours and in at
least 87% of iterations at 48 hours. CONCLUSION: Atosiban
was cost-saving versus beta-mimetics in the treatment of preterm
labour in Germany from the payer’s, hospital’s and combined
perspectives. The results were robust in the probabilistic sensi-
tivity analysis.
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OBJECTIVE: Given the complexity of the Medicare Part D
(MPD) prescription drug beneﬁt, many Medicare beneﬁciaries
lack the knowledge and experience to select optimal MPD pre-
scription drug plans. This challenge is exacerbated in low-income
and other vulnerable populations. A Cost-Minimization Analysis
(CMA) was performed to determine whether and to what extent
student pharmacists’ interventions reduce out-of-pocket
(OOP) prescription drug plan costs for Medicare beneﬁciaries.
METHODS: Trained student pharmacists throughout California
provided one-on-one MPD prescription drug plan consultations
during community outreach events. Cost information for the
participant’s current and lowest-cost plan for 2008 was obtained
by conducting a personalized plan search using the online MPD
Plan Finder tool. RESULTS: Twenty-two outreach events were
conducted statewide and data were collected from 250 Medicare
beneﬁciaries. The mean  SD age of the participants was
74.3  9.1 years, and 91 (36.4%) were male. The mean  SD
(range) number of prescription drugs per participant was
5.6  3.9 (0–26). Eighty-three participants (33.2%) had limited
or no English proﬁciency, 82 (32.8%) had less than a high school
education, and 102 (40.8%) were enrolled in both Medicare and
Medicaid. Data from 95 participants (72 of whom were not
enrolled in a MPD drug plan during 2007 and 23 of whom had
incomplete data) were necessarily excluded for purposes of the
CMA. For the other 155 participants, the median annual OOP
costs for continued enrollment in their current MPD prescription
drug plan in 2008 were $440.00, compared to $200.00 for the
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